Exelixis, Inc. (EXEL)
45.45
+0.22
(+0.49%)
USD |
NASDAQ |
Jan 15, 16:00
45.45
0.00 (0.00%)
After-Hours: 18:08
Exelixis SG&A Expense (TTM): 530.03M for Sept. 30, 2025
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Vanda Pharmaceuticals, Inc. | 214.26M |
| ADMA Biologics, Inc. | 96.37M |
| Aldeyra Therapeutics, Inc. | 9.186M |
| Natera, Inc. | 1.121B |
| Merck & Co., Inc. | 10.70B |